Xilio Therapeutics, Inc. insider trading

XLONASDAQ

$9.00-0.11 (-1.21% today)

“Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” — Peter Lynch

Insider Trading vs Stock Price data

Showing the 1Y range: Oct 6, 2025 to Oct 6, 2026. Price (-22.1%). 0 insider transactions plotted in this window as 0 markers; nearby trades of the same kind are grouped.

Transactions plotted on the price chart
Date	Category	Person	Role	Action	Amount	Change in holding

Open market purchase

Open market sell

Marker size reflects transaction size.

Net dollar flow · Buy / Sell balance

Premium

Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Unlock quarterly net flow

Key players

GSGilead Sciences, Inc.10% Owner11.2475%of company
RRRene RussoPRESIDENT AND CEO0.402%of company
JSJames Samuel ShannonDirector0.1729%of company
KLKatarina LuptakovaCHIEF MEDICAL OFFICER0.0411%of company
CJChristopher James FrankenfieldChief Financial Officer0.0306%of company
KMKevin M. BrennanSVP, FINANCE AND ACCOUNTING0.0079%of company

AI Activity Analysis

Premium

Coming soonAI reads of insider activity will appear here for Premium accounts.

Insider activity

Fromto

Company	Insider / role	Action	ΔOwn	Avg price	Amount
XLO	James Samuel ShannonDirector	Open market purchase$44K	+100.0%	$8.79	$44K	Mar 26, 2026	Mar 30, 2026
XLO	Kevin M. BrennanSVP, FINANCE AND ACCOUNTING	Open market sell$1.17K	-22.3%	$0.64	$1.17K	Jan 2, 2026	Jan 5, 2026
XLO	Christopher James FrankenfieldChief Financial Officer	Open market sell$4.5K	-22.1%	$0.64	$4.5K	Jan 2, 2026	Jan 5, 2026

End of history · 3 transactions